November 21, 2017 09:08 AM EST

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

John Carroll

Editor & Founder

Encouraged by evidence of the impact that its diabetes drug semaglutide can have on obesity, with patients shedding an average of 16% of their weight …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

John Carroll

Editor & Founder

Sign up to read this article for free.

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

Chinese drugmaker receives FDA warning letter after management hindered inspection

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend

Are programs with compounded GLP-1s safe for your population?

Build­ing on im­pres­sive da­ta, No­vo Nordisk maps big PhI­II obe­si­ty pro­gram for block­buster hope­ful semaglu­tide

John Carroll

Editor & Founder

Sign up to read this article for free.

GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out

Chi­nese drug­mak­er re­ceives FDA warn­ing let­ter af­ter man­age­ment hin­dered in­spec­tion

Bio­gen, UCB de­tail re­sponse rates in Phase 3 lu­pus tri­al af­ter sur­pris­ing suc­cess

J&J, Pro­tag­o­nist re­veal two Phase 3 wins for oral IL-23 drug that's ex­pect­ed to be a block­buster

NICE has 'done all we can' to ne­go­ti­ate for En­her­tu cov­er­age, reaf­firms de­ci­sion not to rec­om­mend

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Building on impressive data, Novo Nordisk maps big PhIII obesity program for blockbuster hopeful semaglutide

GSK plots regulatory filings for PBC itch after positive Phase 3 readout

Chinese drugmaker receives FDA warning letter after management hindered inspection

Biogen, UCB detail response rates in Phase 3 lupus trial after surprising success

J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that's expected to be a blockbuster

NICE has 'done all we can' to negotiate for Enhertu coverage, reaffirms decision not to recommend

Are programs with compounded GLP-1s safe for your population?